AtriCure Reports Third Quarter 2024 Financial Results
AtriCure reported strong Q3 2024 financial results with worldwide revenue reaching $115.9 million, up 17.9% year-over-year. U.S. revenue grew 16.8% to $95.5 million, while international revenue increased 23.3% to $20.5 million. The company achieved 20% growth in U.S. open appendage management devices and generated positive cash flow of $16.3 million. Gross profit was $86.8 million with a 74.9% margin. The company updated its full-year 2024 revenue guidance to $459-462 million, representing 15-16% growth, and maintained its Adjusted EBITDA guidance of $26-29 million.
AtriCure ha riportato risultati finanziari solidi per il terzo trimestre del 2024, con un fatturato globale che ha raggiunto 115,9 milioni di dollari, in aumento del 17,9% rispetto all'anno precedente. Il fatturato negli Stati Uniti è cresciuto del 16,8% a 95,5 milioni di dollari, mentre il fatturato internazionale è aumentato del 23,3% a 20,5 milioni di dollari. L'azienda ha registrato una crescita del 20% nei dispositivi per la gestione delle appendici aperte negli Stati Uniti e ha generato un flusso di cassa positivo di 16,3 milioni di dollari. L'utile lordo è stato di 86,8 milioni di dollari con un margine del 74,9%. L'azienda ha aggiornato le previsioni di fatturato per l'intero anno 2024 a 459-462 milioni di dollari, rappresentando una crescita del 15-16%, e ha mantenuto le previsioni per l'EBITDA rettificato a 26-29 milioni di dollari.
AtriCure informó resultados financieros sólidos para el tercer trimestre de 2024, con ingresos globales alcanzando 115,9 millones de dólares, lo que representa un aumento del 17,9% en comparación con el año anterior. Los ingresos en Estados Unidos crecieron un 16,8% hasta 95,5 millones de dólares, mientras que los ingresos internacionales aumentaron un 23,3% hasta 20,5 millones de dólares. La compañía logró un crecimiento del 20% en los dispositivos de gestión de apéndices abiertos en EE. UU. y generó un flujo de caja positivo de 16,3 millones de dólares. La ganancia bruta fue de 86,8 millones de dólares con un margen del 74,9%. La compañía actualizó su guía de ingresos para todo el año 2024 a 459-462 millones de dólares, representando un crecimiento del 15-16%, y mantuvo su guía de EBITDA ajustado de 26-29 millones de dólares.
AtriCure는 2024년 3분기 재무 결과에서 전 세계 매출이 1억 1,590만 달러에 이르며, 전년 대비 17.9% 증가했다고 보고했습니다. 미국 매출은 16.8% 증가하여 9,550만 달러에 도달했고, 국제 매출은 23.3% 증가하여 2,050만 달러에 달했습니다. 회사는 미국에서 열린 부속물 관리 장치에서 20% 성장률을 기록했으며, 1,630만 달러의 긍정적인 현금 흐름을 창출했습니다. 총 이익은 8,680만 달러에 74.9%의 마진을 기록했습니다. 회사는 2024년 전체 연도에 대한 매출 전망을 4억 5,900만 달러에서 4억 6,200만 달러로 업데이트하였으며, 이는 15-16% 성장에 해당하고, 조정된 EBITDA 목표를 2,600만 달러에서 2,900만 달러로 유지했습니다.
AtriCure a annoncé des résultats financiers solides pour le troisième trimestre 2024, avec un chiffre d'affaires mondial atteignant 115,9 millions de dollars, en hausse de 17,9% par rapport à l'année précédente. Le chiffre d'affaires aux États-Unis a augmenté de 16,8% pour atteindre 95,5 millions de dollars, tandis que le chiffre d'affaires international a augmenté de 23,3% pour atteindre 20,5 millions de dollars. L'entreprise a réalisé une croissance de 20% dans les dispositifs de gestion des appendices ouverts aux États-Unis et a généré un flux de trésorerie positif de 16,3 millions de dollars. Le bénéfice brut était de 86,8 millions de dollars avec une marge de 74,9%. L'entreprise a mis à jour ses prévisions de chiffre d'affaires pour l'année 2024 à 459-462 millions de dollars, représentant une croissance de 15-16%, et a maintenu ses prévisions d'EBITDA ajusté à 26-29 millions de dollars.
AtriCure berichtete über solide finanzielle Ergebnisse für das dritte Quartal 2024, mit einem weltweiten Umsatz von 115,9 Millionen Dollar, was einem Anstieg von 17,9% im Vergleich zum Vorjahr entspricht. Der Umsatz in den USA wuchs um 16,8% auf 95,5 Millionen Dollar, während der internationale Umsatz um 23,3% auf 20,5 Millionen Dollar anstieg. Das Unternehmen erzielte ein Wachstum von 20% bei den offenen Appendage-Management-Geräten in den USA und generierte einen positiven Cashflow von 16,3 Millionen Dollar. Der Bruttogewinn betrug 86,8 Millionen Dollar mit einer Marge von 74,9%. Das Unternehmen aktualisierte seine Umsatzprognose für das Gesamtjahr 2024 auf 459-462 Millionen Dollar, was einem Wachstum von 15-16% entspricht, und hielt seine angepasste EBITDA-Prognose von 26-29 Millionen Dollar bei.
- Worldwide revenue increased 17.9% YoY to $115.9 million
- U.S. revenue grew 16.8% to $95.5 million
- International revenue rose 23.3% to $20.5 million
- Generated positive cash flow of $16.3 million
- Strong gross margin of 74.9%
- Raised full-year 2024 revenue guidance to $459-462 million
- Operating loss of $7.4 million in Q3 2024
- Net loss per share of $0.17
- Sequential revenue decline of 0.3% from Q2 2024
- Gross margin decreased 27 basis points YoY
Insights
AtriCure's Q3 2024 results demonstrate robust growth with
The raised full-year revenue guidance of
The strong adoption of AtriCure's innovative product portfolio, particularly the ENCOMPASS® clamp, AtriClip® Flex·V® device and cryoSPHERE® probes, validates the company's market position in surgical treatments for atrial fibrillation. The
-
Worldwide revenue of
– an increase of$115.9 million 17.9% year over year -
U.S. revenue of – an increase of$95.5 million 16.8% year over year -
Achieved
20% growth on revenues from open appendage management devices in theU.S. -
International revenue of
– an increase of$20.5 million 23.3% year over year -
Positive cash flow generation of
in third quarter 2024$16.3 million
“Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout our business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “During the quarter, we launched several new products in
Third Quarter 2024 Financial Results
Revenue for the third quarter 2024 was
Gross profit for the third quarter 2024 was
Adjusted EBITDA for the third quarter 2024 is
Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP financial measures. We discuss these non-GAAP financial measures and provide reconciliations to GAAP measures later in this release.
2024 Financial Guidance
AtriCure now expects full year 2024 revenue of approximately
Conference Call
AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, October 29, 2024 to discuss third quarter 2024 financial results. To access the webcast, please visit the Investors page of AtriCure’s corporate website at https://ir.atricure.com/events-and-presentations/events. Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the presentation will be available for 90 days following the presentation.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly known as Twitter) @AtriCure.
Forward-Looking Statements
This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. This press release also includes forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/forward-looking-statements as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. Except where otherwise noted, the information contained in this release is as of October 29, 2024. We assume no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.
Use of Non-GAAP Financial Measures
To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in
Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue to both management and investors.
Adjusted EBITDA is calculated as net income (loss) before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, acquisition costs, legal settlement costs, impairment of intangible assets and change in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)” later in this release.
Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments in fair value of contingent consideration liabilities, impairment of intangible assets, debt extinguishment and legal settlements. A reconciliation of adjusted loss per share reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Loss Per Share” later in this release.
The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financials measures included in this press release, and not to rely on any single financial measure to evaluate our business.
ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, Except Per Share Amounts) (Unaudited)
|
|||||||||||||||
Three Months Ended
|
|
Nine Months Ended
|
|||||||||||||
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
United States Revenue: |
|
|
|
|
|
|
|
||||||||
Open ablation |
$ |
30,601 |
|
|
$ |
25,844 |
|
|
$ |
90,661 |
|
|
$ |
77,988 |
|
Minimally invasive ablation |
|
11,117 |
|
|
|
10,893 |
|
|
|
35,263 |
|
|
|
31,900 |
|
Pain management |
|
16,314 |
|
|
|
12,591 |
|
|
|
44,059 |
|
|
|
36,249 |
|
Total ablation |
|
58,032 |
|
|
|
49,328 |
|
|
|
169,983 |
|
|
|
146,137 |
|
Appendage management |
|
37,420 |
|
|
|
32,364 |
|
|
|
111,257 |
|
|
|
98,647 |
|
Total |
|
95,452 |
|
|
|
81,692 |
|
|
|
281,240 |
|
|
|
244,784 |
|
International Revenue: |
|
|
|
|
|
|
|
||||||||
Open ablation |
|
8,607 |
|
|
|
8,007 |
|
|
|
25,679 |
|
|
|
23,015 |
|
Minimally invasive ablation |
|
1,681 |
|
|
|
1,578 |
|
|
|
5,559 |
|
|
|
4,820 |
|
Pain management |
|
1,590 |
|
|
|
547 |
|
|
|
3,768 |
|
|
|
1,214 |
|
Total ablation |
|
11,878 |
|
|
|
10,132 |
|
|
|
35,006 |
|
|
|
29,049 |
|
Appendage management |
|
8,580 |
|
|
|
6,466 |
|
|
|
24,784 |
|
|
|
18,869 |
|
Total International |
|
20,458 |
|
|
|
16,598 |
|
|
|
59,790 |
|
|
|
47,918 |
|
Total revenue |
|
115,910 |
|
|
|
98,290 |
|
|
|
341,030 |
|
|
|
292,702 |
|
Cost of revenue |
|
29,117 |
|
|
|
24,421 |
|
|
|
86,125 |
|
|
|
72,147 |
|
Gross profit |
|
86,793 |
|
|
|
73,869 |
|
|
|
254,905 |
|
|
|
220,555 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Research and development expenses |
|
20,960 |
|
|
|
20,354 |
|
|
|
61,221 |
|
|
|
53,119 |
|
Selling, general and administrative expenses |
|
73,238 |
|
|
|
61,604 |
|
|
|
219,174 |
|
|
|
185,451 |
|
Total operating expenses |
|
94,198 |
|
|
|
81,958 |
|
|
|
280,395 |
|
|
|
238,570 |
|
Loss from operations |
|
(7,405 |
) |
|
|
(8,089 |
) |
|
|
(25,490 |
) |
|
|
(18,015 |
) |
Other expense, net |
|
(126 |
) |
|
|
(919 |
) |
|
|
(2,882 |
) |
|
|
(2,416 |
) |
Loss before income tax expense |
|
(7,531 |
) |
|
|
(9,008 |
) |
|
|
(28,372 |
) |
|
|
(20,431 |
) |
Income tax expense |
|
322 |
|
|
|
47 |
|
|
|
758 |
|
|
|
218 |
|
Net loss |
$ |
(7,853 |
) |
|
$ |
(9,055 |
) |
|
$ |
(29,130 |
) |
|
$ |
(20,649 |
) |
Basic and diluted net loss per share |
$ |
(0.17 |
) |
|
$ |
(0.20 |
) |
|
$ |
(0.62 |
) |
|
$ |
(0.45 |
) |
Weighted average shares used in computing net loss per share: |
|
|
|
|
|
|
|
||||||||
Basic and diluted |
|
47,105 |
|
|
|
46,411 |
|
|
|
46,912 |
|
|
|
46,262 |
|
ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands) (Unaudited)
|
|||||||
September 30,
|
|
December 31,
|
|||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash, cash equivalents, and short-term investments |
$ |
130,335 |
|
|
$ |
137,285 |
|
Accounts receivable, net |
|
54,909 |
|
|
|
52,501 |
|
Inventories |
|
76,546 |
|
|
|
67,897 |
|
Prepaid and other current assets |
|
7,496 |
|
|
|
8,563 |
|
Total current assets |
|
269,286 |
|
|
|
266,246 |
|
Property and equipment, net |
|
43,537 |
|
|
|
42,435 |
|
Operating lease right-of-use assets |
|
6,100 |
|
|
|
4,324 |
|
Goodwill and intangible assets, net |
|
293,133 |
|
|
|
298,767 |
|
Other noncurrent assets |
|
3,012 |
|
|
|
2,160 |
|
Total Assets |
$ |
615,068 |
|
|
$ |
613,932 |
|
Liabilities and Stockholders' Equity |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable and accrued liabilities |
$ |
71,716 |
|
|
$ |
72,036 |
|
Current lease liabilities |
|
2,715 |
|
|
|
2,533 |
|
Total current liabilities |
|
74,431 |
|
|
|
74,569 |
|
Long-term debt |
|
61,865 |
|
|
|
60,593 |
|
Finance and operating lease liabilities |
|
12,548 |
|
|
|
11,368 |
|
Other noncurrent liabilities |
|
1,203 |
|
|
|
1,234 |
|
Total Liabilities |
|
150,047 |
|
|
|
147,764 |
|
Stockholders' Equity: |
|
|
|
||||
Common stock |
|
49 |
|
|
|
48 |
|
Additional paid-in capital |
|
851,306 |
|
|
|
824,170 |
|
Accumulated other comprehensive loss |
|
(147 |
) |
|
|
(993 |
) |
Accumulated deficit |
|
(386,187 |
) |
|
|
(357,057 |
) |
Total Stockholders' Equity |
|
465,021 |
|
|
|
466,168 |
|
Total Liabilities and Stockholders' Equity |
$ |
615,068 |
|
|
$ |
613,932 |
|
ATRICURE, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS (In Thousands) (Unaudited)
|
|||||||||||||||
Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA) |
|||||||||||||||
Three Months Ended
|
|
Nine Months Ended
|
|||||||||||||
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
Net loss, as reported |
$ |
(7,853 |
) |
|
$ |
(9,055 |
) |
|
$ |
(29,130 |
) |
|
$ |
(20,649 |
) |
Income tax expense |
|
322 |
|
|
|
47 |
|
|
|
758 |
|
|
|
218 |
|
Other expense, net |
|
126 |
|
|
|
919 |
|
|
|
2,882 |
|
|
|
2,416 |
|
Depreciation and amortization expense |
|
4,928 |
|
|
|
4,111 |
|
|
|
13,907 |
|
|
|
10,634 |
|
Share-based compensation expense |
|
10,364 |
|
|
|
8,661 |
|
|
|
30,020 |
|
|
|
26,416 |
|
Gain from legal settlements |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(4,412 |
) |
Non-GAAP adjusted income (adjusted EBITDA) |
$ |
7,887 |
|
|
$ |
4,683 |
|
|
$ |
18,437 |
|
|
$ |
14,623 |
|
Reconciliation of Non-GAAP Adjusted Loss Per Share |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Net loss, as reported |
$ |
(7,853 |
) |
|
$ |
(9,055 |
) |
|
$ |
(29,130 |
) |
|
$ |
(20,649 |
) |
Loss on debt extinguishment |
|
— |
|
|
|
— |
|
|
|
1,362 |
|
|
|
— |
|
Gain from legal settlements |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(4,412 |
) |
Non-GAAP adjusted net loss |
$ |
(7,853 |
) |
|
$ |
(9,055 |
) |
|
$ |
(27,768 |
) |
|
$ |
(25,061 |
) |
Basic and diluted adjusted net loss per share |
$ |
(0.17 |
) |
|
$ |
(0.20 |
) |
|
$ |
(0.59 |
) |
|
$ |
(0.54 |
) |
Weighted average shares used in computing adjusted net loss per share |
|
|
|
|
|
|
|
||||||||
Basic and diluted |
|
47,105 |
|
|
|
46,411 |
|
|
|
46,912 |
|
|
|
46,262 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029706905/en/
Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Marissa Bych
Gilmartin Group
Investor Relations
(415) 937-5402
marissa@gilmartinir.com
Source: AtriCure, Inc.
FAQ
What was AtriCure's (ATRC) revenue growth in Q3 2024?
What is AtriCure's (ATRC) revenue guidance for full-year 2024?
What was AtriCure's (ATRC) cash flow in Q3 2024?